Co-Authors
This is a "connection" page, showing publications co-authored by RAVI MURTHY and ADI DIAB.
Connection Strength
0.150
-
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022 12 01; 28(23):5079-5087.
Score: 0.055
-
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. Cancer Discov. 2021 08; 11(8):1996-2013.
Score: 0.049
-
Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. JAMA Netw Open. 2020 07 01; 3(7):e207911.
Score: 0.046